• Linda García-Hidalgo, Silvia Méndez-Flores, Sandra Carrillo-Vázquez, Lorena Estrada-Aguilar, Ma Del Rosario García-Salazar, Minerva Gómez-Flores, Adriana López-Tello, Yann Charli-Joseph, César Maldonado-García, and Liliana Serrano-Jaén.
• Academia Mexicana de Dermatología, Ciudad de México, México.
• Gac Med Mex. 2020 Jan 1; 156 (Supl): 1-14.

AbstractThe development and marketing of biosimilars opens a new scenario in the treatment of many pathologies, including psoriasis. This article reflects the position of the Mexican Academy of Dermatology (AMD) on the use of biosimilar medicines for the treatment of psoriasis in Mexico. In summary, the AMD estates that there is sufficient evidence to accept comparability of pharmacokinetics and pharmacodynamics of some biosimilar medicines to adalimumab, infliximab and etanercept; this evidence does not sufficiently support interchangeability or indication extrapolation. It is essential to establish a close pharmacovigilance not only to guarantee compliance with the Cofepris rules in Mexico, but also to facilitate the effective monitoring of the adverse effects of biosimilar medicines. Although the goal of biotechnological drugs is to achieve substantial savings for patients and public institutions, no economic criteria should prevail over rigorous scientific criteria that guarantee maximum therapeutic efficacy and optimum safety for patients.Copyright: © 2020 Permanyer.

30 keywords...

hide…